Creative Medical Technology Holdings Announces Filing of 2022 Form 10-K and Provides Business Update

About this update from Creative Medical Technology Holdings, Inc.

[{"type":"text","content":"PHOENIX, April 4, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (\"Creative Medical Technology\" or the \"Company\" or \"We\") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced the filing of its Form 10-K on March 31, 2023 for the year ended December 31, 2022 (FY 2022) and provided a summary of the progress made in 2022 and thus far in 2023.\n\n \n \n \n \n \n \n\n \n\"2022 was a year of significant clinical, regulatory, and partnership milestones, and our efforts in these areas have continued in earnest during 2023,\" said Timothy Warbington, Chief Executive Officer of Creative Medical Technology. \"We ended the year in a strong financial position that provides us with a cash runway to continue to support the development of best-in-class regenerative therapeutics to address multiple indications, including immunology, endocrinology, urology, gynecology, and orthopedics. As we continue through 2023, we believe that our extensive IP portfolio, seasoned leadership, strong partnerships, and growing addressable end markets will support our clinical advancements and serve as the foundation for further focusing our pipeline development. We look forward to 2023 with optimism.\"\nClinical Updates\nPhase 1 / 2 Clinical Trial: we are excited about our Phase 1/2 randomized, controlled clinical trial (CELZ-201) for the treatment of early Type 1 Diabetes using AlloStem™ was cleared by the U.S. Food and Drug Administration (FDA) in Q4 2022 and IRB approved in Q1 2023. This first-in-country clinical trial delivers allogenic cellular therapy in the dorsal artery of the pancreas and is designed to leverage what we believe is the unique approach using AlloStem™ to harness the multi-potent power of Perinatal Tissue Derived Cells, which will not require any immunosuppression.Orphan Drug Designation: in Q1 2023, we filed an application with the FDA to receive Orphan Drug Designation for the treatment of patients with Brittle Type 1 Diabetes using our ImmCelz® platform with human islet cell transplantation. This combination has been designated as CELZ-101.Product Advancements and Partnerships\nMaster Collaboration Agreement: in Q1 2022, we entered into a Master Collaboration Agreement with the world-renowned University ...

More updates from Creative Medical Technology Holdings, Inc.